A Human Liver Organoid Screening Platform for DILI Risk Prediction
Authors:
- Charles J. ZhangCZCharles J. Zhang
- Sophia R. MeyerSMSophia R. Meyer
- Matthew J. O’mearaMOMatthew J. O’meara
- Meghan M. CapelingMCMeghan M. Capeling
- Daysha Ferrer-TorresDFDaysha Ferrer-Torres
- Charlie J. ChildsCCCharlie J. Childs
- Jason R. SpenceJSJason R. Spence
- Robert J. FontanaRFRobert J. Fontana
- Jonathan Z. SextonJSJonathan Z. Sexton
Preprint
Abstract
Background and Aims: Drug-induced liver injury (DILI), both intrinsic and idiosyncratic, causes frequent morbidity, mortality, clinical trial failures and post-approval withdrawal. This suggests an unmet need for improved in vitro models for DILI risk prediction that can account for diverse host genetics and other clinical factors. In this study, we evaluated the utility of human liver organoids (HLOs) for high-throughput DILI risk prediction and in an organ-on-chip system. Methods: HLOs were derived from 3 separate iPSC lines and benchmarked on two platforms for their ability to model in vitro liver function and identify hepatotoxic compounds using biochemical assays for albumin, ALT, and AST, microscopy-based morphological profiling, and single-cell transcriptomics: 1) HLOs dispersed in 384-well formatted plates and exposed to a library of compounds. 2) HLOs adapted to a liver-on-chip system. Results: Dispersed HLOs derived from the 3 iPSC lines had similar DILI predictive capacity to intact HLOs in a high-throughput screening format allowing for measurable IC50 values of compound cytotoxicity. Distinct morphological differences were observed in cells treated with drugs exerting differing mechanisms of toxicity. On-chip HLOs significantly increased albumin production, CYP450 expression, and ALT/AST release when treated with known DILI drugs compared to dispersed HLOs and primary human hepatocytes. On-chip HLOs were able to predict the synergistic hepatotoxicity of tenofovir-inarigivir and showed steatosis and mitochondrial perturbation via phenotypic and transcriptomic analysis with exposure to FIAU and acetaminophen, respectively. Conclusions: The high throughput and liver-on-chip system exhibit enhanced in vivo -like function and demonstrate the potential utility of these platforms for hepatotoxicity risk assessment. Tenofovir-inarigivr associated hepatotoxicity was observed and correlates with the clinical manifestation of DILI observed in patients. LAY SUMMARY: Idiosyncratic (spontaneous, patient-specific) drug-induced liver injury (DILI) is difficult to study due to the lack of liver models that function as human liver tissue and are adaptable for large-scale drug screening. Human liver organoids grown from patient stem cells respond to known DILI-causing drugs in both a high-throughput and on a physiological “chip” culture system. These platforms show promise in their use as predictive model for novel drugs before entering clinical trials.Keywords
All Related Versions
- Published version: Journal of Hepatology, 78 (5), 998.
This publication has 49 references indexed in Scilit:
- Glutathione S-Transferase P1 Correlated with Oxidative Stress in Hepatocellular CarcinomaInternational Journal of Medical Sciences, 2013
- Standardization of nomenclature and causality assessment in drug‐induced liver injuryHepatology, 2010
- RNAi-mediated germline knockdown of FABP4 increases body weight but does not improve the deranged nutrient metabolism of diet-induced obese miceInternational Journal of Obesity, 2010
- Mechanisms of Acetaminophen-Induced Liver Necrosis2009
- Pharmacokinetics of Acetaminophen-Protein Adducts in Adults with Acetaminophen Overdose and Acute Liver FailureDrug Metabolism and Disposition, 2009
- Specific role for acyl CoAHepatology, 2009
- Induced Pluripotent Stem Cell Lines Derived from Human Somatic CellsScience, 2007
- Mitochondria: important target for drug toxicity?Journal of Hepatology, 2001
- Mitochondrial Injury Lessons from the Fialuridine TrialDrug Safety, 1997
- Role of CYP2E1 in the Hepatotoxicity of AcetaminophenJournal of Biological Chemistry, 1996